GLP-3R 40 mg

Retatrutide (sometimes nicknamed “GLP‑3”) is a synthetic triple‑receptor agonist peptide developed by Eli Lilly. It is designed to activate three metabolic hormone pathways at once:

1. GLP‑1 receptor — glucagon‑like peptide‑1
2. GIP receptor — glucose‑dependent insulinotropic polypeptide
3. Glucagon receptor — energy and fat metabolism regulation

This multi‑target approach makes it distinct from earlier drugs that target only one (like semaglutide) or two (like tirzepatide) receptors.  

⚙️ How It Works

Retatrutide acts simultaneously on:

🔹 GLP‑1 Receptors

• Reduces appetite and food intake
• Slows stomach emptying
• Improves glucose‑dependent insulin secretion

🔹 GIP Receptors

• Enhances insulin response after meals
• May improve fat metabolism and glucose control
• Works synergistically with GLP‑1 effects

🔹 Glucagon Receptors

• Raises energy expenditure
• Promotes fat oxidation
• May help reduce liver fat and visceral adiposity

Together, these pathways can reduce hunger, improve metabolic control, and increase calorie use more potently than older single‑ or dual‑agonist drugs.